Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom. Teenagers at participating schools are being asked to take part by local research teams involved.

Meningitis is caused by an infection around the surface of the brain. It is rare but can be life-threatening and mostly affects babies, young children and adolescents. An important cause of meningitis is a type of bacteria (or germs) called meningococcus.

For more information, please visit or

What is the ‘Be on the TEAM’ study?

  • This study will see if immunising teenagers with MenB vaccines reduces the carriage of meningococcus in teenager’s throats, which could in turn protect the broader community
  • Teenagers who take part will receive 2 doses of a Meningitis B vaccine
  • These are licensed vaccines that teenagers would not otherwise receive, and will reduce their risk of meningitis
  • Participants would have two throat swabs taken 1 year apart
  • There would be three study visits, over 12 to 18 months
  • All visits would be held within participating schools

Which schools are taking part?

The schools listed below are participating within the Thames Valley

    • Cheney School, Oxford
    • The Grange School, Aylesbury
    • Kennet School, Thatcham
    • King Alfred’s Academy, Wantage
    • Matthew Arnold School, Oxford
    • Our Lady’s School, Abingdon
    • Queen Anne’s School, Caversham
    • Tudor Hall School, Banbury
    • Park House School, Newbury
    • Radley College, Abingdon
    • Magdalen College School, Oxford
    • St Bartholomew's School, Newbury
    • Oxford High School, Oxford
    • Headington School, Oxford

    Where can I find out more information?

    The Oxford Vaccine Group study information booklets contain more information (Information booklet)

    If you would like any further information regarding the study please contact the study team on:


    Tel: 01865611400

    Many thanks,

    The MenB Carriage Team

    Oxford Vaccine Group


    Similar stories

    New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.

    Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

    Oxford Ebola vaccine manufactured and shipped in record time by SII

    More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

    From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

    Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

    Oxford to work with Brazil to establish clinical research hub

    The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

    Phase I trial begins of new vaccine against the Plague

    Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

    Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

    Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.